Robert is one of the UK’s leading experts in pharmaceutical pricing and market access, having held senior positions within HM Treasury, the Department for Health and Social Care, and NHS England on life sciences policy and negotiation.
Most recently, Robert was Director of Medicines Negotiation at NHS England where he led a series of sensitive and technical negotiations across many innovations including ATMPs, multi-indication oncology medicines, and population-health interventions for obesity and CVD. He delivered the first successful combination therapy deals, a groundbreaking outcome-based pricing agreement in haemophilia B, and the implementation of a revolutionary gene therapy for thalassaemia and sickle cell disease via the Innovative Medicines Fund.
Robert was the lead negotiator for the UK Government on the last two voluntary scheme deals which determine the pricing and reimbursement for branded medicines in the UK – the 2019 VPAS and 2024 VPAG – and spent over four years leading the schemes’ operation. He also spent three years as the lead negotiator for the NHS on the GP Contract, including the establishment of new financial incentives for GPs through QOF and Primary Care Networks.